Metastatic HR+/HER2- Breast Cancer Market Projected to Expand Significantly by 2034, Driven by Recent FDA Approvals and Emerging Targeted Therapies | DelveInsight

The metastatic HR+/HER2- breast cancer market is experiencing robust growth, fueled by an increasing patient pool and the introduction of innovative targeted therapies. Key breast cancer companies, such as Pfizer,